There is no known definite treatment after exposure to SARS-CoV-2, but the some animal and clinical trials confirmed the efficacy of hydroxychloroquine (HCQ) or chloroquine against SARS-CoV-2. Thus, in this study, we aim to evaluate the efficacy and safety of hydroxychloroquine as post exposure prophylaxis for SARS-CoV-2. - Primary end point: comparison the rate of COVID-19 between PEP with HCQ and control group. - Secondary end point: Comparison of the rate of COVID-19 according to the contact level (time, place, degree of wearing personal protective equipment). - Safety comparison: Safety verification by identifying major side effects in the HCQ group."
Drug: Hydroxychloroquine as post exposure prophylaxis
1day: Hydroxychloroquine 800mg Qd po 2-5dy: Hydroxychloroquine 400mg Qd po
Other: Others(No intervention)
No treatment. Close monitoring and quarantine.
Inclusion Criteria:
- A contact person from confirmed case of SARS-CoV-2 infection
- Medical staff exposed from confirmed case of SARS-CoV-2 infection in hospitals
- Persons exposed to SARS-CoV-2 in COVID-19 outbreak situation with certain workplaces,
religious groups, and military, etc.
- Subjects of study include both symptomatic and asymptomatic contacts.
Exclusion Criteria:
- Hypersensitivity to Chloroquine or Hydroxychloroquine
- Those who are contraindicated in Hydroxychloroquine administration according to the
permission requirements such as pregnant women, nursing mothers, visual disorders,
macular disease, and porphyria, etc.
- Human immunodeficiency virus (HIV) infected person
- Patients with autoimmune disease (Systemic lupus erythematosus, Mixed connective
tissue disease)
- Patients with autoimmune rheumatoid inflammatory disease (AIIRD; Autoimmune
inflammatory rheumatic diseases - Ankylosing spondylitis, Rheumatic arthritis,
Psoriatic arthritis)
- Arrhythmia, liver cirrhosis of Child Pugh C, chronic renal failure with eGFR≤30mL /
min / 1.73m2
- A person who is positive in the COVID-19 screening PCR test before starting PEP
Gangnam Severance Hospital
Seoul, Korea, Republic of
Yong Goo Song, Professor, Principal Investigator
Gangnam Severance Hospital